HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 937-943

  Phuphuakrat, Angsana ^a   Pasomsub, Ekawat ^a   Kiertiburanakul, Sasisopin ^a   Chantratita, Wasun ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR;

ADULT; ALGORITHM; AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THAILAND; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; INTEGRASE INHIBITORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; THAILAND;

EID: 84864197719     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0139     Document Type: Article

References (46)

1. Menendez-Arias L: Molecular basis of human immunodeficiency virus drug resistance: An update. Antiviral Res 2010;85:210-231.
2. FDA approves raltegravir tablets: AIDS Patient Care STDS 2007;21:889.
3. U.S. Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, 2009.
4. Engelman A, Bushman FD, and Craigie R: Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 1993;12:3269-3275.
5. Engelman A and Craigie R: Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 1992;66:6361-6369.
6. Burke CJ, Sanyal G, Bruner MW, et al.: Structural implications of spectroscopic characterization of a putative zinc finger peptide fromHIV-1 integrase. J BiolChem1992;267:9639-9644.
7. Lee SP, Xiao J, Knutson JR, Lewis MS, and Han MK: Zn2 + promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry 1997;36:173-180.
8. Zheng R, Jenkins TM, and Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci USA 1996;93:13659-13664.
9. Kulkosky J, Jones KS, Katz RA, Mack JP, and Skalka AM: Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol 1992;12:2331-2338.
10. Savarino A: In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007;4:21.
11. Lutzke RA, Vink C, and Plasterk RH: Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res 1994;22:4125-4131.
12. Goethals O, Clayton R, Van Ginderen M, et al.: Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82:10366-10374.
13. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, and Pommier Y: Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drugresistant integrase mutants. Biochemistry 2008;47:9345-9354.
14. Shimura K, Kodama E, Sakagami Y, et al.: Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir ( JTK-303/GS-9137). J Virol 2008;82:764-774.
15. Charpentier C, Karmochkine M, Laureillard D, et al.: Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;9:765-770.
16. Cooper DA, Steigbigel RT, Gatell JM, et al.: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-365.
17. Malet I, Delelis O, Valantin MA, et al.: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52:1351-1358.
18. JohnsonVA, Brun-Vezinet F, Clotet B, et al.:Update of the drug resistance mutations in HIV-1. Top HIVMed 2008;16:138-145.
19. Garrido C, Geretti AM, Zahonero N, et al.: Integrase variability and susceptibility to HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010;65:320-326.
20. Bar-Magen T, Donahue DA, McDonough EI, et al.: HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 2010;24:2171-2179.
21. Passaes CB, Guimaraes ML, Fernandez SL, et al.: Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr 2009;51:7-12.
22. Eshleman SH, Hudelson SE, Smith P, et al.: Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses 2009;25:343-345.
23. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, and Papathanasopoulos MA: Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 2010;26:489-493.
24. Lataillade M, Chiarella J, and Kozal MJ: Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007;12:563-570.
25. Auswinporn S, Jenwitheesuk E, Vibhagool A, Sookpranee M, Leechawengwong M, and Chantratita W: Genotypic subtyping of the HIV-1 polymerase gene in 30 naive patients from Thailand. Southeast Asian J Trop Med Public Health 2001;32:346-350.
26. Wirachsilp P, Kantakamalakul W, Foongladda S, et al.: Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. Southeast Asian J Trop Med Public Health 2007;38:814-827.
27. Isarangkura-Na-Ayuthaya P, Kaewnoo W, Auwanit W, et al.: Appearance of drug resistance-associated mutations in human immunodeficiency virus type 1 CRF01-AE integrase derived from drug-naive Thai patients. AIDS Res Hum Retroviruses 2010;26:1341-1343.
28. Nouhin J, Donchai T, Hoang KT, et al.: Natural polymorphisms of HIV-1 CRF01-AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: An ANRS AC12 working group study. Infect Genet Evol 2011;11:38-43.
29. Low A, Prada N, Topper M, et al.: Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53:4275-4282.
30. van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, and Dwyer DE: HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 2009; 6:12.
31. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al.: Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: The recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008;91:1925-1935.
32. Campanella JJ, Bitincka L, and Smalley J: MatGAT: An application that generates similarity/identity matrices using protein or DNA sequences. BMC Bioinformatics 2003;4:29.
33. Nei M and Gojobori T: Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986;3:418-426.
34. Rose PP and Korber BT: Detecting hypermutations in viral sequences with an emphasis on G/A hypermutation. Bioinformatics 2000;16:400-401.
35. Arroyo MA, Phanuphak N, Krasaesub S, et al.: HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses 2010;26:5-12.
36. Avi R, Huik K, Sadam M, et al.: Characterization of integrase region polymorphisms in HIV type 1 CRF06-cpx viruses in treatment-naive patients in Estonia. AIDS Res Hum Retroviruses 2010;26:1109-1113
37. Goethals O, Vos A, Van Ginderen M, et al.: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with secondgeneration resistance profiles. Virology 2010;402:338-346.
38. da SilvaD, VanWesenbeeck L, Breilh D, et al.: HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010;65:1262-1269.
39. Hombrouck A, Voet A, Van Remoortel B, et al.: Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother 2008;52:2069-2078.
40. Yang Z, Nielsen R, Goldman N, and Pedersen AM: Codonsubstitution models for heterogeneous selection pressure at amino acid sites. Genetics 2000;155:431-449.
41. Bourara K, Litvak S, and Araya A: Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing. Science 2000;289:1564-1566.
42. Land AM, Ball TB, Luo M, et al.: Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 2008;82:8172-8182.
43. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, and Siliciano RF: G/A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 2005;79:1975-1980.
44. Myers RE and Pillay D: Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008;82:9228-9235.
45. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, and Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009;11:17-29.
46. Ceccherini-Silberstein F, Malet I, Fabeni L, et al.: Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 2010;65:2305-2318.